Comprehensive Genomic Profiling (CGP) in the U.S. - Medical Oncologist, Medium Midwestern IHN

A medical oncologist considers CGP crucial for treatment decision-making, emphasizing the need for CGP to include a PD-L1 testing in addition to mutation profiling. The stakeholder discusses the CGP vendor landscape as a whole, singling out those they use most frequently, companies they see as declining in share, and offerings that introduced impactful late entries.The interviewee expects potential changes in the vendor CGP usage at their IHN. Additionally, they expect CGP to become the standard of care in the future, but they recognize several limitations such as turnaround time, cost, and nonspecific targets in CGP panels. When it comes to the potential for increasing in-house testing capabilities, they highlight the importance of turnaround time and third-party billing. Overall, the stakeholder anticipates changes in turnaround times and improvements in technology in the future.

‍